16-0029-85

antibody from Invitrogen Antibodies

Targeting: CD2 SRBC

Flow cytometry (Recommended by provider)

Blocking/Neutralizing (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

16-0029-85

Provider

Invitrogen Antibodies

Product name

CD2 Monoclonal Antibody (RPA-2.10), Functional Grade, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The RPA-2.10 monoclonal antibody reacts with human CD2, a 50 kDa cell surface receptor expressed by a majority of thymocytes, all mature T cells and subset of NK cells. CD2 is a ligand for CD58 in the human and is involved in adhesion and activation of T cells. RPA-2.10 blocks mixed lymphocyte reaction. RPA-2.10 crossreacts to non-human primates and pigs. Applications Reported: The RPA-2.10 antibody been reported for use in flow cytometric analysis. RPA-2.10 has also been reported in blocking of CD2 activity in in vitro functional assays. Applications Tested: This RPA-2.10 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

Reactivity

Human, Porcine

Host

Mouse

Isotype

IgG

Antibody clone number

RPA-2.10

Vial size

500 µg

Concentration

1 mg/mL

Storage

4° C

References

Submitted references

Constraints on GPCR Heterodimerization Revealed by the Type-4 Induced-Association BRET Assay.

Felce JH, MacRae A, Davis SJ
Biophysical journal 2019 Jan 8;116(1):31-41

---

A monoclonal antibody selection for immunohistochemical examination of lymphoid tissues from non-human primates.

Kap YS, van Meurs M, van Driel N, Koopman G, Melief MJ, Brok HP, Laman JD, 't Hart BA
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Dec;57(12):1159-67

---

Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy.

Schierloh P, Yokobori N, Alemán M, Landoni V, Geffner L, Musella RM, Castagnino J, Baldini M, Abbate E, de la Barrera SS, Sasiain MC
Infection and immunity 2007 Nov;75(11):5325-37

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Type-4 BRET assay applied to known controls. ( A ) The mean Delta BRET eff of type-1 transmembrane protein controls using the FKBP 1 type-4 BRET assay. Only the known dimers CD28 and CD80 exhibited significantly nonzero Delta BRET eff when expressed as homomeric pairs. Dark gray bars indicate like-like pairs. ( B ) The mean Delta BRET eff of type-1 transmembrane protein controls using the FKBP 3 type-4 BRET assay. Delta BRET eff is larger for CD28 and CD80 than with the FKBP 1 approach. ( C ) A histogram of CD2 expression in HEK-293T cells transfected with 1 mu g of differently tagged forms of CD2, as measured by flow cytometry. ( D ) Confocal microscopy of CD28-GFP coexpressed with CD28-FKBP 1/3 in the presence and absence of AP20187. No clear GFP internalization was evident. ( E ) The mean Delta BRET eff of GPCRs of known stoichiometry using the FKBP 3 type-4 BRET assay. For all panels, bars indicate mean +- SD. Probability is indicated for difference from Delta BRET eff = 0; * p < 0.05, *** p < 0.005. All data are the result of n >= 3 independent experiments.